Aptuit Completes Evotec CPD Acquisition

Aptuit, Inc. has completed the acquisition of Evotec‘s Chemical and Pharmaceutical Development (CPD) business. The move allows Aptuit to integrate an API facility in Oxford, England and a recently expanded parenteral fill/finish facility in Glasgow, Scotland into its global network.

According to an Aptuit statement, “The integration of these development and small-scale manufacturing facilities in Europe completes a unique global API supply chain where small scale development takes place in the U.S. and Europe with commercial scale undertaken in new state-of-the-art facilities in India.”

“Over the past 18 months we’ve assembled by strategic acquisitions the core competencies that are key to reducing the time and cost burdens of drug development for our customers, and that also build on our commitment to operate an efficient, integrated global network. This particular acquisition is an important building block for Aptuit as we move toward completing that network,” said Michael A. Griffith, Aptuit’s chief executive officer and founder.